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The advent of recombinant genetic engineering techniques has revolu-
tionized biotechnology. The biomedicine and biotechnology industries
have extensively employed these techniques to improve the quality of agri-
cultural crops and livestock and to create genetically modified organisms
("GMOs") in order to produce drugs. Since as much as twenty-five percent
of the world's intellectual property-related trade involves biotechnology,
many countries have realized the importance of providing intellectual prop-
erty protection for biotechnological technologies, including GMOs)
In the past decade, China's booming economy has helped make its bio-
technological market the fastest growing market in the world. To stimulate
innovation and attract private investment in its biotechnology industry,
China has rapidly transformed its intellectual property laws to conform with
western models in the last two decades. However, plants and animals are
not patentable in China. While plant varieties enjoy sui generis system pro-
tection, animal varieties are not protected by any law. This poses a serious
problem for biotechnology firms that have heavily invested in the research
and development of genetically modified animals.
This article focuses on whether China should provide intellectual prop-
erty protection for new animal varieties, including genetically modified
animals. Section II offers a brief introduction to the development of re-
combinant genetic engineering techniques. Section III discusses the bene-
fits and risks of GMOs. The ethical issues of animal patenting are
* J.D. Candidate, May 2003, Northwestern University School of Law.
'See Ramona L. Taylor, Tearing Down the Great Wall. China's Road to WTO Acces-
sion, 41 J.L. & TECH. 151 (2001).
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discussed in section IV. Sections V and VI present an overview of interna-
tional and China's intellectual property protection for GMOs, respectively.
Section VII concludes with a discussion of why and how China should pro-
vide intellectual property protection for genetically engineered animals.
II. THE DEVELOPMENT OF RECOMBINANT GENETIC ENGINEERING
TECHNIQUES
The genetic material of living organisms has long been manipulated to
produce desired characteristics in new organisms. Plant and animal breed-
ers have employed intraspecies crossings and selections for desirable char-
acteristics and eventual stabilization of the new traits for centuries.' Since
the discovery that deoxyribonucleic acid (DNA) is the genetic material
which encodes all biological information, scientists have used induced
mutagenesis to modify DNA and select desirable traits.3 This new method
accelerates the conventional breeding process that may normally take gen-
erations unaided.4 However, both approaches present the same challenge:
the selection process can be extremely painful and fruitless because the
modification of DNA is random and the outcome is unpredictable.
Recombinant genetic techniques employed during the past three dec-
ades have revolutionized biotechnology. The creation of a transgenic or-
ganism involves the introduction of a foreign gene into the organism. A
living organism may generally be genetically transformed after four steps:
(1) a desired gene is isolated in its native form; (2) the gene is characterized
and modified into a shorter DNA form at the molecular level; (3) the de-
sired DNA sequence is inserted into an appropriate vector which can be in-
tegrated into the chromosomal DNA of the target organism; and (4) the
vector containing the foreign DNA is introduced into the organism. 6 The
foreign gene, which can either add to or replace the native gene, remains
part of the transformed organism permanently.7
The rapid development of modern molecular biology techniques has
made recombinant genetic engineering a feasible and routine practice in
numerous laboratories around the world. Compared to the traditional ge-
netic approaches, recombinant genetic engineering has two major advan-
2 See STEPHEN A. BENT ET AL., INTELLECTUAL PROPERTY RIGHTS IN BIOTECHNOLOGY
WORLDWIDE 19-28 (1987).
3 See id. at 20 (for instance, chemical agents and irradiation have been used to induce
mutagenesis of DNA).
4 Id. (induced mutagenesis allows breeders quicker and more direct access to genetic ma-
terials than the traditional process, where breeders only can artificially select mutants based
on organismic criteria).5 1d.
6 E.S. VAN DE GRAFF, PATENT LAW AND MODERN BIOTECHNOLOGY 20 (1997).
71d. at 29.
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tages. First, it is time and cost efficient. Most of the equipment and facili-
ties required for genetic transformation are commercially available and rela-
tively inexpensive. Also, modem DNA vectors are highly efficient at
delivering the foreign DNA into the chromosomal DNA of the target organ-
ism.8 Second and more importantly, equipped with the knowledge about the
functions and characteristics of foreign DNA, a genetic engineer may pre-
dict the traits of the transformed organism and thus "overcome the random-
ness of heritability associated with conventional plant and animal
breeding." 9
Recombinant genetic engineering has profoundly changed agriculture
as well as the biomedical and pharmaceutical industries. In plant agricul-
ture, researchers have successfully added disease resistance genes, herbicide
tolerance genes, and pest resistance genes into various crops.'° Crops can
also be engineered to be more nutritious and productive."' Furthermore,
through genetic engineering, livestock animals have become more produc-
tive and have acquired more disease resistance.' 2 For example, transgenic
swine consume significantly less feed but arrive at market weight faster
than their native counterparts.' 3 The pharmaceutical industry has also in-
creasingly utilized genetically modified animals or microorganisms to pro-
duce drugs to cure or alleviate diseases, 14 such as AIDS, cancer and
hepatitis B.1
5
China's biotechnological market has grown faster than any other in the
world in the past decade.' 6 To narrow the gap between its biomedical in-
dustry and those of developed countries, China has employed two main ap-
proaches. First, China decided to focus its research and resources in several
key fields, one of which is genetic engineering. 17 For example, China's
State Science and Technology Commission ("SSTC") launched several
programs to support biotechnology research, development, and commer-
cialization.' 8 Second, China has vigorously campaigned for investments
from foreign pharmaceutical companies and has enjoyed tremendous suc-
81d. at 22.
9 Reid G. Adler, Controlling the Applications ofBiotechnology: A Critical Analysis of the




3 1d. at 21.
14 Akim F. Czmus, Biotechnology Protection in Japan, the European Community, and the
United States, 8 TEMP. INT'L. & COMP. L.J. 435 (1994).
5 d. at 436.
16 Market Research Studies. Expert Market Devises Improving 1997 Global Market,
BIOMEDICAL MARKET NEWSL., Apr. 30, 1997.
11 Development of Biomedicine in China, MARKETLETTER, Sept. 8, 1997.
18 Andrew Beckman, Biomed & Biotech New Business Opportunities in China (PRC),
BIOMEDICAL MARKET NEWSL., Apr. 1, 1996.
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cess. For example, by 1997 China had received a $4.1 billion capital in-
vestment from about 1,500 foreign pharmaceutical companies,' 9 including
Merck from the United States, Genset from France, and Kirin Brewery Co.
from Japan. 20 As a result, China is viewed in the international biotechnol-
ogy arena as an emerging power.
III. THE BENEFITS AND RISKS OF GMOS
GMOs, like any other innovation, provide both benefits and risks.
Many of the major benefits of GMOs have already been mentioned. For
example, genetic engineering can significantly increase the productivity of
crops and livestock, which may be extremely vital to deal with the expected
food shortfalls accompanying the rapid expansion of the world's popula-
tion. Genetic engineering can also be used to improve the quality of food.2'
Furthermore, the drugs produced by GMOs have been tremendously bene-
ficial to human health because of their high quality, ability to be produced
in large quantities and relatively low prices. In addition, adding certain
disease genes to animals can provide researchers with non-human models to
research the cures for diseases such as hypertension and AIDS.2
The risks associated with GMOs can be divided into three categories:
environmental, economic and those affecting human health.23 The envi-
ronmental arguments against patenting GMOs focus on GMOs' effects on
the ecosystem and the reduction of biodiversity.24 Some commentators ar-
gue that the introduction of GMOs "into an ecosystem might affect the dy-
namics of the ecosystem or the gene pool of wild relatives., 25 For example,
crops with herbicide resistance genes may transfer these genes to weeds,
thus creating a major threat to the environment.2 6 Furthermore, patenting
opponents point out that humans often lack the wisdom and foresight as to
19 Dan Gallagher, China Offering Biotech Firms Big Opportunities, SAN DIEGO DAILY
TRANSCRIPT, June 17, 1997, at Al.
20 Leslie Cataldo, A Dynasty Weaned from Biotechnology: the Emerging Face of China,
26 SYRACUSE J. INT'L L. & CoM. 151, 164-66 (1998).
21 Carrie F. Walter, Intellectual Property Law Review 1999, 31 INTELL. PROP. L. REV.
195,219 (1999).
22 Patents and the Constitution: Transgenic Animals: Hearings Before the Subcomm. On
Courts, Civil Liberties and the Administration of Justice of the House of Representative
Comm. On the Judiciary, 100th Cong. 36-37, 47-49 (1988) (testimony of Thomas E. Wag-
ner, Professor of Molecular Biology and Director, Edison Animal Biotechnology Center,
Ohio State University).
23 Henrique Freire de Oliveira Souza, Genetically Modified Plants: A Need for Interna-
tional Regulation, 6 ANN. SURV. INT'L & COMP. L. 129, 138 (2000).
24 Adler, supra note 9, at 38-43.
25 Souza, supra note 23, at 139.
26 Michael A. Whittaker, Reevaluating the Food and Drug Administration's Stand on La-
belling Genetically Engineered Foods, 35 SAN DIEGO L. REV. 1215, 1220-21 (1998).
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the disastrous consequences of interfering with the environment. 27 For in-
stance, humans released the gypsy moth and kudzu vine into the environ-
ment and caused extremely serious damages.28
The view that GMOs represent an environmental threat is not necessar-
ily the predominant view, however. For example, a report prepared for the
National Academy of Sciences concluded that there was "adequate knowl-
edge of the relevant scientific principles, as well as sufficient experience
with recombinant DNA engineered organisms, to guide the safe and prudent
use of such organisms outside research laboratories.,, 29 Furthermore, it is
relatively easy for scientists to monitor and control the transfer of genes be-
tween GMOs and wild organisms by mating.
30
Opponents of animal and plant patenting also argue that the introduc-
tion of GMOs might result in loss of biodiversity if such new varieties
dominate. 31 The loss of biodiversity could have disastrous consequences in
agriculture because high genetic uniformity means that the agricultural
crops and livestock are more susceptible to common diseases or pest infes-
tation.3 2 For example, more than ninety-five percent of chicken eggs are
from a single breed, White Leghorns, and more than ninety percent of milk
is from the breed Holstein.33 Thus, a lethal disease to either breed could
ruin the milk or chicken egg industry.34
Patenting advocates respond that there is no causal link between pat-
ents and a decrease in biodiversity. 35 As one commentator points out, there
already has been a decrease in biodiversity in the livestock industry because
of increased corporate consolidation; genetic engineering might reverse this
trend by adding foreign genes into crops and creating new varieties.36
The main economic argument against the patenting of GMOs is that
the initial acquisition prices and subsequent royalties of GMOs will in-
crease costs for both farmers and consumers.37 However, this view fails to
consider the basic principles of economics, as farmers would not acquire or
27 Rebecca Dresser, Ethical and Legal Issues in Patenting New Animal Life, 28
JURIMETRICS J. 399, 411-12 (1988).
28id
29 Report from Committee on the Introduction of Genetically Engineered Organisms into
the Environment to the Council of the National Academy of Sciences, Introduction of Re-
combinant DNA-Engineered Organisms into the Environment: Key Issues 6 (1987) (on file
with author).
30 Dresser, supra note 27, at 414.
" See Adler, supra note 9, at 43.
'2 Id. at 44.
33 Barry Hoffmaster, The Ethics of Patenting Higher Life Forms, 4 1. P. J. 1, 14 (1988).
(Intellectual Property Journal?)34 id.
35 Adler, supra note 9, at 44-46.
36 Id. at 45-46.
37 Walter, supra note 21, at 211.
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use GMOs if their economic benefits did not outweigh the costs.
The question of whether GMOs may be safely used as food for humans
remains unanswered. As of today, there is no answer because of a lack of
scientific data and a lack of uniformity in the safety standards of different
countries. 38 However, the bottom line is that there are already many lawful
but unsafe foods on the market.39
IV. ETHICAL ISSUES OF ANIMAL PATENTING
Opposition to animal patenting is mainly based on ethical grounds. In
general, patenting critics express concern about several issues: human arro-
gance, devaluation of human life, and animal welfare.4 °
Patenting opponents argue that patenting reflects a view of life which
is completely human-centered. 4' Animal patents allow the commercializa-
tion of animals' lives and reflect the view that all natural resources are for
human exploitation and animals are no different from chemical products.
42
However, this argument is not persuasive because for thousands of years
humans have treated animals as properties by buying, selling, and using
them for humanity's commercial and consumer needs.43
Patenting opponents also argue that by creating and patenting geneti-
cally engineered animals, humans violate animals' right to exist as separate
species. 44 In response, patenting advocates point out that there are no abso-
lute rules to separate species, and humans have already created many ge-
netically altered animals through traditional breeding techniques.45
A stronger argument against animal patenting is that patenting animals
would eventually lead to the patenting of human life and the creation of
human-animal hybrids.46 One commentator analogizes the problem to a
slippery slope by pointing out that humans will inevitably become pat-
entable subject matter if animals are patentable because it is theoretically
and empirically impossible to draw a clear distinction between animal and
human life. 47 Furthermore, adding human genes to animals may create hu-
man-animal hybrids.48 As they have successfully created a "geep," a hybrid
of goat and sheep, scientists may as well create a hybrid of human and
38 Souza, supra note 23, at 139-40.
39 Id. at 140.
40 See Dresser, supra note 27, at 410; Adler, supra note 9, at 46-50.
41 See Dresser, supra note 27, at 411.
42 Id.
41 Id. at 413.
44 See Adler, supra note 9, at 48-49.
45 See Dresser, supra note 27, at 413-14.
46 See Hoffmaster, supra note 33, at 11; Dresser, supra note 27, at 415.
47 See Hoffmaster, supra note 33, at 11-12; Dresser, supra note 27, at 416.
48 Dresser, supra note 27, at 415-16.
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chimpanzee. 49 Patenting opponents argue that this disturbing scenario will
not only reduce the value of human life to chemical molecules, but also
"violate the cultural taboo against procreation between animals and hu-
mans."
50
In responding to this line of criticism, the proponents of animal patent-
ing argue that currently the quantity of human genes added to animals is too
small to create human-animal hybrids. 5' More importantly, they argue that
the genuine ethical concern about human-animal hybrids should be ad-
dressed in the policies regulating genetic engineering research, not in patent
law.52
Finally, patenting opponents argue that allowing animal patenting
would stimulate transgenic research and result in more animal suffering.53
However, this line of argument overlooks the beneficial side of genetic ma-
nipulation. 54 Transgenic research can produce animals with stronger resis-
tance to diseases. 55 Patenting will also benefit animals because genetic
engineering usually results in less unplanned negative results occurring in
traditional breeding.56
In summary, many of the ethical arguments against animal patenting
are not compelling. Furthermore, many of these concerns should be ad-
dressed in policies regulating transgenic research, not patent law.
V. INTERNATIONAL INTELLECTUAL PROPERTY PROTECTION FOR GMOs
The patentability of GMOs, especially genetically modified animals, is
a highly controversial issue. Most countries either allow plant varieties to
be patented, provide an effective sui generis system, or some combination
of the two. They probably find that the need to provide more food to the
geometrically expanding population outweighs potential environmental
risks. However, many countries refuse to provide any protection, patent or
otherwise, to new animal varieties, despite the fact that the creation of new
animal varieties involves very similar techniques to those used to produce
new plant varieties.5 7 The discrepancy of treatment between these countries





5 Id. at 417.
51 See id. at 422-23.
54 See Adler, supra note 9, at 37.
15 See id.
56 See Dresser, supra note 27, at 423.
57 BENT ET AL., supra note 2, at 24-25.
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A. GMOs Patentable in the U.S.
In the landmark decision Diamond v. Chakrabarty,58 the U.S. Supreme
Court held that a living microorganism is patentable subject matter under §
101 of the Patent Act. 59 The Court further held that living matter is pat-
entable if it is the result of human intervention.60 In 1987, the Commis-
sioner of the Patent and Trademark Office ("PTO") announced that animals
may be patented.6 The first animal patent was issued in 1988 to a trans-
genic non-human mammal, which was genetically engineered to be more
susceptible to carcinogens.62
Plant varieties are also protected by a variety of Acts. Asexually re-
produced plant varieties are patentable under the Plant Patent Act
("PPA"). 6 3 The Patent Variety Protection Act ("PVPA") of 1970 provides
patent-like protection to sexually reproduced plants.64 Additionally, accord-
ing to Chakrabarty, plants may also be patented.
B. Union for the Protection of New Varieties of Plant ("UPOV")
In many civil law countries, plant varieties are not patentable because
they lack novelty, invention, utility, or the ability to replicate or repro-
duce.65 Instead, these countries established "separate legal regimes for spe-
cial protection of plant varieties" which later developed into UPOV.
66
UPOV protects biological innovations which do not meet the requirements
of patent protection.6 7 Thus, both plant and animal varieties fall within the
protection zone of UPOV. It should be noted, however, that UPOV protects
only the whole plant or animal, not its genes or constituent chemicals.
68
447 U.S. 303 (1980).
5935 U.S.C. § 101 (1952).
60 Diamond, supra note 58, at 309.
61 1077 OFFICIAL GAZ. PAT. OFF. 24 (1987).
62 U.S. Patent No. 4,736,866 (issued Apr. 12, 1988).
63 35 U.S.C. §§ 161-164 (1954).
64 7 U.S.C. § 2321-2583 (1982).65 See Geertrui Van Overwalle, Patent Protection for Plants: A Comparison of American
and European Approaches, 39 J.L. & TECH. 143, 148 (1999).
66 Lester Ross & Libin Zhang, Agricultural Development and Intellectual Property Pro-
tection for Plant Varieties: China Joins the UPOV, 17 UCLA PAC. BASfN L.J. 226, 229
(1999).
67 See Klaus Bosselmann, Plants and Politics: The International Legal Regime Concern-
ing Biotechnology and Biodiversity, 7 COLO. J. INT'L ENVTL. L. & POL'Y 111, 122-23 (1996).6 1ld. at 124.
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C. Trade Related Aspects of Intellectual Property Rights ("TRIPS")
TRIPS, a division of the World Trade Organization ("WTO"), requires
member states to provide intellectual property protection for all biotechno-
logical inventions. 69 Concerning plant varieties, TRIPS requires WTO
members to "provide for the protection of plant varieties either by Patents
or by an effective sui generis system or any combination thereof., 70 Devel-
oped countries embrace TRIPS because this universally-accepted system
provides much needed protection for their advanced biotechnology indus-
tries.7' In 1990, TRIPS proposed to allow patenting living organisms,
which include microorganisms, plants and animals. 72 However, this pro-
posal was opposed by developing countries and did not pass. 73 Since its en-
try into the WTO in November 2001, China has been bound by TRIPS to
provide required intellectual property protection for biotechnological inven-
tions.74
VI. INTELLECTUAL PROPERTY PROTECTION FOR GMOs IN CHINA
China has experienced tremendous economic growth since it opened
its doors to western countries in 1978. China has also rapidly transformed
its intellectual property laws according to western models. In 1984, China
passed its first patent law that was compatible with international stan-
dards.75 That law extended fifteen years of patent protection to inventions
and five years to utility models and designs after the patent applications
were filed.76 Pharmaceuticals were not patentable subject matter under the
1984 law.77 The 1993 amendments to the patent law extended protection to
chemicals and pharmaceuticals.78 In addition, patent terms were extended
69 General Agreement on Tariffs and Trade, Oct. 30, 1947, 61 Stat. A-11, T.I.A.S. 1700,
55 U.N.T.S. 194.
70 Agreement on Trade Related Aspects of Intellectual Property Rights [hereinafter
TRIPS agreement], Art. 27.3(b).
71 See David G. Scalise & Daniel Nugent, Comment, International Intellectual Property
Protection for Living Matter: Biotechnology, Multinational Conventions and the Exception
for Agriculture, 27 CASE W. RES. J. iNT'L L. 83, 114-115 (1995).
72 Id
73 Cataldo, supra note 20, at 158.
74 See Thomas T. Moga, China Changes Patent Law to Comply with TRIPS, NAT'L L.J.,
July 23, 2001, at C15.
75 See Jill Chiang Fung, Note, Can Mickey Mouse Prevail in the Court of the Monkey
King? Enforcing Foreign Intellectual Property Rights in the People's Republic of China, 18
Loy. L.A. INT'L & COMP. L. REV. 613, 627 (1996).
76 See David B. Dreyfus, Note, Confucianism and Compact Discs: Alternative Dispute
Resolution and its Role in the Protection of United States Intellectual Property Rights in
China, 13 OHIO ST. J. ON Disp. RESOL. 947, 952 (1998).
77 Id.
78 See Fung, supra note 75, at 632.
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under the 1992 amendment. 79 Inventions are entitled to a twenty-year pro-
tection while utility models and designs are protected for ten years. Thus,
the amended Patent Law of 1993 was in greater conformity with interna-
tional standards.
Despite this greater conformity, however, plant and animal varieties
are not patentable, although China permits the patenting of microbiological
processes and their derivative products.80 The reasons to deny patent pro-
tection for plant and animal varieties are not clear.8'
VII. PLANT VARIETY RIGHTS
With an enormous and ever expanding population, China has realized
that the focus of agricultural science and technology is on developing,
through genetic engineering, new animal and plant varieties with higher
quality and productivity. 82 However, the lack of a patent or sui generis pro-
tection system deprives breeders of the incentive to expend resources on re-
search and development of new plant or animal varieties. As a result, the
technical level of China's agricultural and life sciences lags behind that of
developed countries and the gap is still widening.83
In 1997, China passed the Regulations on the Protection of New Varie-
ties of Plants (the "Plant Variety Regulations") with the objective of pro-
moting the development of agriculture and forestry.84 To qualify for Variety
Rights, the plant varieties must be (1) novel, (2) distinctive from all other
varieties prior to application, (3) stable with regard to their relevant proper-
ties after reproduction, (4) properly named, and (5) belonging to a plant
species included in the State plant varieties catalogue.8 5
Once awarded Variety Rights, the breeder enjoys an exclusive right to
the plant variety. Specifically, "no unit or individual may for commercial
purposes (i) produce or sell any breeding material for which Variety Rights
have been awarded or (ii) make repeated use of such breeding material to
create new varieties. 86 A Variety Rights holder can subject infringers to
79 See Patent Law of the People's Republic of China, art. 45 (1993) (P.R.C.) [hereinafter
China Patent Law].80 See Davis Hill & Judith Evans, Chinese Patent Law: Recent Changes Align China
More Closely With Modern International Practice, 27 GEO. WASH. J. INT'L L. & ECON. 359,
364 (1993-1994).
8 See China Patent Law, art. 25 (1993) (P.R.C.).
82 Ross & Zhang, supra note 66, at 230-31.
83 See Bosselmann, supra note 67, at 121-22.
84 See the Regulations of People's Republic of China on the Protection of New Varieties
of Plants [hereinafter Plant Variety Regulations], art. 1 (1997), available at http://
www.cnpvp.net/old-www/rules-and regulations.htm.85 See Plant Variety Regulations, art. 13-17.
86 Ross & Zhang, supra note 66, at 232-33.
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both civil litigation and administrative mediation.
87
Variety Rights provide narrower protection for plant varieties than pat-
ents.88 For instance, anyone can use a plant variety under the protection of
Variety Rights for breeding or other scientific research activities without
compensating the Variety Rights holder.89 Farmers can also freely utilize
the "breeding material for their own use." 90 Furthermore, once awarded the
Rights, most plant varieties are protected for only 15 years compared to the
20-year term under the Patent Law.9' In China, both the Patent Law and the
Plant Variety Regulations have a compulsory licensing provision.92 Under
this provision, the approving authority can compel an awardee to license his
patent or new plant variety even at below-market prices or to his competi-
tors.93 This provision is rather problematic because it fails to clearly state
restrictions on the exercise of compulsory licensing.94
Despite any shortcomings, the Plant Variety Regulations comply with
the TRIPS agreement, which requires WTO member nations to provide at
least one effective protection system for plant varieties.95 Although it is not
very clear as to why China chose the Plant Variety protection over patent
protection, most developing countries oppose the idea of patenting living
organisms because they cannot afford the expensive licensing fees of
GMOs and also because much of the starting genetic material used for
GMOs is native to their lands.96
VIII. RESOLUTION OF PATENT DISPUTES
China developed a two-track system to enforce intellectual property
rights. The first track is the administrative resolution where the infringed
party files a complaint with local administrative offices that are responsible
for patent-related affairs. 97 Once a complaint is filed, the administrative au-
thorities first mediate the disputing parties to a reconciliation or settlement.
If mediation fails, the patent administrative authorities have the power to
order either monetary compensation or an injunction against the infringer.98
Administrative resolution remains the dominant method for patent-
87 See Plant Variety Regulations, supra note 84, at art. 39.
88 Ross & Zhang, supra note 66, at 233.
g9 Id.
90 Id.
91 See Plant Variety Regulations, supra note 84 at art. 34.
92 See id. at art. 11. See also China Patent Law, supra note 79, at art. 57-58 (1993).
93 Ross & Zhang, supra note 66, at 233.
9' Id. at 233-34.
95 Id. at 230.
96 See Cataldo, supra note 20, at 155.
97 See Moga, supra note 74, at C16. These offices are also called Patent Administrative
Authorities. See Hill & Evans, supra note 80, at 372.
98 See Hill & Evans, supra note 80, at 373.
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related disputes in China for various reasons. The Chinese have a tradition
of preferring conciliation between adversarial parties over litigation because
of their long-held concept of "amity above all." 99 The administrative ap-
proach is also fast and efficient-a dispute can be resolved within days after
the complaint is filed.'00 Part of the reason for the efficiency is that the lo-
cal authorities are closely connected to other local agencies, whose coopera-
tion is instrumental to the enforcement. 10 1 Furthermore, the administrative
approach is an inexpensive alternative to litigation because of its relatively
low costs. 1
02
The administrative approach cannot replace the judicial approach,
however. Importantly, it lacks the deterrent feature of the judicial approach
because the Patent Administrative Authorities cannot impose criminal pen-
alties on the infringers. In addition, the administrative approach often re-
sults in limited temporary relief because the victim of a government raid is
usually not the source of the infringing products, but the distributor.' 
03
On the other hand, the second track, the judicial approach, offers last-
ing and deterrent remedies, including compensatory damages, punitive
damages, or criminal punishment. 10 4 However, the judicial approach is not
the preferred method of patent disputes. The process is slow and many
judges are not adequately trained with regard to patent-related issues.10 5 In
addition, the financial burden on the aggrieved party can be substantial be-
cause the complaint filing fees are proportional to the requested amounts of
damages. 106
IX. THE EFFECTS OF THE 2001 AMENDMENTS TO CHINA'S PATENT LAW
The 2001 amendments brought China's Patent Law more in line with
the TRIPS agreement.'0 7 Specifically, there are four major changes worth
noting. First, the pre-2001 Patent Law allowed compulsory licensing of
patents under a broad provision,'0 8 which was inconsistent with Article 31
of the TRIPS agreement. 0 9 The 2001 amendments define the subject mat-
99 d. at 392.
00 See Moga, supra note 74, at C16.
101 See Hill & Evans, supra note 80, at 392.
02 Id. at 376.





07 d. at C15.
lo See China Patent Law, supra note 79, at art. 53 (1993) (permitting compulsory licens-
ing to a patent when the exploitation of a later and more advanced patent depends on the ex-
ploitation the earlier patent).
109 TRIPS agreement, supra note 70, at art. 31 (permitting compulsory licensing only un-
der reasonably well-defined circumstances).
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ter and relative value of a patent that could be subject to compulsory licens-
ing.l° Furthermore, the time, scope, and duration of compulsory licenses
have also been amended to be consistent with the TRIPS agreement.
111
Second, the 2001 Patent Law provides a patentee with the exclusive
right of sale. 1 12 Although the TRIPS agreement requires WTO member na-
tions to award patent holders the right to "exclude others from offering for
sale the patented products or products directly obtained by patented proc-
esses," China's former Patent Law did not have such a provision.1 13 The
2001 amendment to Article 11 of the Patent Law erased the inconsis-
tency.
114
Third, the amended Patent Law shifts the burden of proof to the alleged
patent infringer in infringement cases. Article 57 of the new Patent Law
states that "[f]or any dispute as to infringement regarding the patent for in-
vention which relates to a process for the manufacture of a new product, the
entity or individual that produces the same products has responsibility to
provide evidence demonstrating that its process is different from the pat-
ented process. ' 15 This change makes China's Patent Law compliant with
the TRIPS agreement.' 6
The last major change to the Patent Law is the allowance of injunctive
relief as a critical mechanism of patent enforcement.1 17 This amendment is
also consistent with Article 44(1) of the TRIPS agreement.' 18
The 2001 amendments notwithstanding, challenges for the inventors
still remain. Under the new Patent Law, animals and plants are still not
patentable subjects. 1 9 Although plant varieties enjoy protection under the
Plant Variety Regulations, animal varieties are not protected by any law.
Furthermore, the provisions regarding compulsory licensing in both the
Patent Law and the Plant Variety Regulations are too broad and thus not in
compliance with the TRIPS agreement. For example, the Patent Law does
not clearly define the restrictions on the exercise of compulsory licensing
power. 120 The Patent Law also fails to state that a patent holder shall be
paid "adequate remuneration in the circumstances" as required by Article
31 (h) of the TRIPS agreement.121
10 Moga, supra note 74, at C15.
1 See id. at C16. See also China Patent Law, supra note 79, at art. 52 (2001).
112 See Moga, supra note 74, at C15.
13 Id. See also TRIPS agreement, supra note 70, at art. 28.
114 See also China Patent Law, supra note 79, at art. 11 (2001).
"5 See China Patent Law, supra note 79, at art. 57 (2001).
116 See TRIPS agreement, supra note 70, at art. 34(1).
117 See China Patent Law, art. supra note 79, at 61 (2001).
118 See TRIPS agreement, supra note 70, at art. 44(1).
i"9 See China Patent Law, supra note 79, at art. 25 (2001).
120 See Moga, supra note 74, at C16.
121 TRIPS agreement, supra note 70,at art. 3 1(h).
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Because the 2001 Patent Law remains silent about the patentability of
animal varieties, the next section will mainly discuss whether new animal
varieties should enjoy intellectual property protection in China.
X. SHOULD NEW ANIMAL VARIETIES BE PROTECTED IN CHINA?
China's ever growing population and increasing demand for food
might require the country to provide intellectual property protection for new
animal varieties. Such protection of animal varieties may encourage both
domestic and foreign investment in biotechnology research and develop-
ment in China. Furthermore, protection would promote the transfer of bio-
technologies to China. However, due to economic concerns, animal patents
might be unwise. A sui generis protection system such as the Plant Varie-
ties Regulations might be more appropriate.
XI. INTELLECTUAL PROPERTY PROTECTION FOR ANIMAL VARIETIES
IMPORTANT TO CHINA
Patent protection grants an inventor exclusive rights to make, use, and
sell the patented invention.' 22 The promise of protection induces inventors
to spend resources on research and development, thus advancing technol-
ogy by stimulating innovation. 23 This is especially true for the biotechnol-
ogy industry because the costs of developing new drugs or GMOs can be
intimidating. 124 The absence of intellectual property protection for new
animal varieties, including genetically modified animals, can harm animal
research. For example, the biomedicine and biotechnology industries
would have no incentive to develop and commercialize the genetically
modified animals used to produce important drugs to cure human dis-
eases. 125 Farmers may also suffer economic losses where intellectual prop-
erty protection does not exist because there would be fewer transgenic
livestock animals with higher productivity or improved resistance to dis-
eases. 126 Intellectual property protection for new animal varieties is particu-
larly important to China because of its growing need for food.
XII. CHINA'S POPULATION EXPANSION NECESSITATES MORE FOOD
ANIMALS
Animals provide the major source of protein for human beings. 127 The
122 See Adler, supra note 9, at 12.
123 Id.
124 See VAN DE GRAAF, supra note 6, at 38.
125 See Adler, supra note 9, at 7-8.
126 Id. at 8.
127 Id. at 33 (although the data about the composition of the Chinese diet are not avail-
able, in the United States, "food animals provide seventy percent of the protein, thirty-five
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world's population is expanding geometrically; therefore, the demand for
food animals is also increasing rapidly.' 28 The problem of inadequate food
supplies becomes more pressing as the use of land has reached saturation
level.
With 1.25 billion people, China is the most populated country in the
world. 129 Although China is currently able to feed its population, the tradi-
tional agricultural crops and livestock will probably not be able to meet the
increasing demand of food coupled with its expanding population. The
most viable solution to this problem is the development and adoption of
more productive and nutritious crops and livestock. 30 Modem genetic en-
gineering technologies can create transgenic livestock that grow faster, con-
sume less food, and are leaner and more nutritious than traditional breeds.' 3 '
Furthermore, transgenic cattle produce more milk per animal while con-
suming less food.'
32
Without intellectual property protection of genetically modified ani-
mals, however, the biotechnology industry in China would have little incen-
tive to invest in the research and development of more productive livestock.
Furthermore, without protection, foreign biotechnology companies have lit-
tle incentive to introduce their new animal varieties into China. Therefore,
transgenic animals should be protected in China to stimulate agricultural
innovation and promote cross-border technology transfers, which will in
turn help solve the anticipated food shortfall.
XIII. INTELLECTUAL PROPERTY PROTECTION FOR GENETICALLY
MODIFIED ANIMALS WILL ACCELERATE THE DEVELOPMENT OF CHINA'S
BIOMEDICINE AND PHARMACEUTICAL INDUSTRIES
The advent of DNA recombinant technologies and genetically modi-
fied animals promises major breakthroughs for the biomedicine and phar-
maceutical industries. Many human genes have been transferred into
laboratory animals to study their regulations and functions. For example,
the cellular receptor for the AIDS virus only exists in humans and chimpan-
zees.133 While experiments on chimpanzees are extremely expensive, intro-
ducing the receptor gene into mice can produce an inexpensive animal
percent of the energy, eighty percent of the calcium, sixty percent of the phosphorus, and
significant proportion of vitamins and minerals consumed").128 id.
129 See Taylor, supra note 1.
130 OFFICE OF TECHNOLOGY ASSESSMENT, U.S. CONGRESS, PUB. No. OTA-F-285,
TECHNOLOGY, PUBLIC POLICY, AND YHE CHANGING STRUCTURE OF AMERICAN AGRICULTURE
3 (1986).
131 See Adler, supra note 9, at 5.
132 id.
113 Id. at 21-22.
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model to study AIDS and to screen AIDS drugs.1 34 Research on transgenic
animals bearing human genes can greatly enhance Our ability to understand
human and animal physiology, including the immune system, genetic defi-
ciencies, embryonic development, and viral diseases. 135
Transgenic animals may also function as molecular farms to produce
drugs to cure or alleviate human diseases. For example, transgenic sheep
were created to produce human blood clotting factors used for the treatment
of hemophiliacs.' 36 Transgenic mice were also created to produce tissue
plasminogen activator ("TPA") used to treat heart attacks.137 Compared to
the chemical synthesis approach, the "molecular farming" approach is much
more accurate and cost-efficient.
Intellectual property protection is the decisive reason why pharmaceu-
tical companies invest in research and development.138 Because of the high
commercial stakes involved, pharmaceutical companies need to protect
their products against imitations after they introduce the products into the
market. Given the fact that the costs of GMO development are extremely
high and many biotechnological innovations are made by small start-up
companies, intellectual property protection is necessary to allow small
companies to recover their expenses. 139
China has invested heavily on genetic and protein engineering during
the last decade in order to raise its biotechnology industry level to that of
the developed countries.140 For example, China's State Science and Tech-
nology Commission established the "Torch Program" to promote the com-
mercialization, industrialization, and globalization of China's new
technologies. The biotechnology part of this program focuses on the re-
search and development of biopharmaceutical products, such as hepatitis B
vaccines and anti-tumor drugs. 42 The Chinese Academy of Sciences has
also sponsored many biomedical projects, including the development of in-
terleukin-2, interferon alpha, and hepatitis B vaccines. 43
Although the majority of China's biomedical research is funded by the
government, China plans to significantly decrease governmental funding
and eventually make private firms, both foreign and domestic, finance the
134 Id.
35 Camper, Research Application of Transgenic Mice, 5 BIOTECHNIQUEs 638 (1987).36 Adler, supra note 9, at 5.
137 id
138 See VAN DE graff, supra note 6, at 37.
"' Id. at 38.140 See Development of Biomedicine in China, supra note 17.
141 See Beckman, supra note 18.
142 Id.
143 See Development of Biomedicine in China, supra note 17.
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research and development of biomedical products.144 However, without
proper intellectual property protection for new animal varieties, private
firms have little incentive to risk the intimidating costs of research and de-
velopment. As a result, not only will China's agriculture suffer the absence
of more productive, nutritious, and disease resistant livestock, but also the
Chinese people will be deprived of the access to the high-quality and inex-
pensive drugs produced by transgenic animals. The lack of intellectual
property protection for new animal varieties will directly defeat China's
goal of developing a competitive biotechnology industry.
XIV. TRADE SECRET LAW NOT A SUFFICIENT PROTECTION FOR
GENETICALLY MODIFIED ANIMALS
In the absence of appropriate intellectual property protection for ge-
netically modified animals, inventors will have to resort to trade secret law
to safeguard their investment on research and development. Even if trade
secret law can provide sufficient protection for genetically modified ani-
mals, it will deprive society of cutting-edge biotechnological information
and cause people to waste resources in penetrating commercial secrecy.
45
The more troubling problem, however, is that trade secret law is not a
sufficient protection for genetically modified animals because of the nature
of genetic engineering techniques. Trade secret law requires some degree
of secrecy and also requires the inventors undertake spend reasonable ef-
forts to protect the secrecy. However, some of the unique attributes of ge-
netically modified animals make them very difficult to protect. 46 For
example, a misappropriator can easily recreate a transgenic animal by steal-
ing the DNA sequence written in a piece of paper.' 47 Advances in genetic
engineering techniques make gene transformation a routine practice in an
adequately equipped laboratory. Therefore, once a competitor misappropri-
ates a genetic code, he can easily recreate the transgenic animal.
In addition, once a misappropriator obtains a genetically engineered
animal, he can regenerate many offspring without even understanding the
genetic information embodied in the animal. The self-generating nature of
organisms is the exact attribute that makes transgenic animals highly desir-
able, but it also inevitably makes the protection of animal variety property
difficult. 14
8
Trade secret laws in the United States and some other countries also
require a trade secret to have "an established commercial value at the time
144 See Beckman, supra note 18.
145 R. POSNER, ECONOMIC ANALYSIS OF LAW 2d 53 (1977).
146 See BENT ET AL., supra note 2, at 346.
147 id.
141 id. at 346-47.
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of theft."'149 This requirement poses another problem for the protection of
genetically modified animals, because many biotechnological inventions do
not have established commercial values if they are still in the basic research
stage. 15 Although they contain substantial research information and are on
the verge of being developed into commercial products,' 51 some countries
152have denied such genetically modified animals trade secret protection.
Thus, trade secret law cannot provide sufficient protection for geneti-
cally modified animals because of their unique attributes. A more exclusive
protection system is needed to safeguard the high costs biotechnology com-
panies spend on the research and development of transgenic animals.
XV. INTELLECTUAL PROPERTY PROTECTION FOR GENETICALLY
ENGINEERED ANIMALS PROVIDED IN MANY COUNTRIES
Many developed countries have provided patent protection for living
organisms, including genetically modified animals. In 1969, Hungary en-
acted a law to extend patent protection to animals if they met the require-
ments of "distinguishable, novel, homogenous and stable."' 53 Germany in
1969 decided that animals were patentable if their production is repeat-
able. 54 Higher life forms, including animals, are also patentable in Austra-
lia.' 5
5
In the landmark Chakrabarty decision, 56 the U.S. Supreme Court con-
cluded that Section 101 of the Patent Act should be broadly construed and
patentable subject matter includes "anything under the sun that is made by
man." 57 Following the Chakrabarty decision, PTO issued the first animal
patent to a genetically engineered mammal in 1988.158 In 1982, Canada
also followed the Chakrabarty decision and treated living organisms as pat-
entable subject matter.' 59 Due to the high economic stakes involved with
genetically modified animals in biomedicine and biotechnology industries,
many more countries are expected to join the trend to include animals in
patentable subject matter.
149 Id. at 348.
150 id.
151 id.
152 Id. at 355.
53 Hungarian Patent Law, art. 71 (1969).
54 See Adler, supra note 9, at 30.
'
55 Id. at 31.
56 47 U.S. 303 (1980).
'5 Id. at 309, (citing S. REP. No. 1979, 82d Cong., 2d Sess. 5 (1952); H.R. REP. No. 1923,
82d Cong., 2d Sess. 6 (1952)).158 U.S. Patent No. 4,736,866 (issued Apr. 12, 1988) (patent issued to a transgenic non-
human mammal which was genetically engineered to be more susceptible to carcinogens).
'59 See Adler, supra note 9, at 30-31.
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XVI. CHINA SHOULD PROVIDE Sui GENERiS SYSTEM PROTECTION FOR
GENETICALLY MODIFIED ANIMALS
Although intellectual property protection for genetically modified ani-
mals is important to China's agriculture and biotechnology industries,
China should not adopt patent protection because of economic reasons.
Due to historical reasons, the technical level of China's life sciences re-
search lags behind that of developed countries and China's intellectual pro-
tection system is geared more towards the importation of advanced
technologies. As a developing country, China prefers to receive free trans-
fer of cutting-edge biotechnologies. 160 Without the benefit of receiving free
technology transfer, China cannot afford the rights to use costly biotechnol-
ogy products.1 61 This is particularly true for the biotechnological inventions
concerning agricultural livestock. Genetically engineered livestock can be
more productive, nutritious, and disease resistant. However, Chinese farm-
ers may be deprived of the benefits of these improved livestock because of
the costly acquisition and royalty fees.
A sui generis protection system such as the Plant Variety Regulations
may serve China better. An animal variety protection system, similar to the
Plant Variety Regulations, would award an animal breeder exclusive rights
to his new animal variety. Under such a system, other units or individuals
cannot for commercial purposes produce or sell the protected variety, or use
it to create new varieties. In this way, a sui generis protection system may
adequately protect the intellectual property rights of biotechnology firms
and safeguard their investment on the research and development of trans-
genic animals.
A sui generis protection system, however, should impose some limita-
tions on the animal variety rights. Like the Plant Variety Regulations, it
should allow farmers to utilize genetically engineered livestock for their
own use without compensating the animal variety rights holder. Further-
more, it should allow others to freely use the protected variety for breeding
or other scientific research activities. In this way, a sui generis protection
system would alleviate China's financial burden to pay for the rights of new
biotechnological inventions.
XVII. CONCLUSION
China should extend intellectual property protection for genetically
modified animals for a variety of reasons. The increasing demand for food
animals can only be met by the development and adoption of genetically
improved agricultural livestock that are more productive, nutritious, and
160 Cataldo, supra note 20, at 155.
161 id.
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disease resistant. Intellectual property protection for new animal varieties
can also protect the investment of biotechnological companies and acceler-
ate the development of China's biomedicine and pharmaceutical industries.
Furthermore, trade secret law cannot provide sufficient protection for
GMOs due to their unique attributes. In addition, many countries have real-
ized the importance of extending intellectual property protection for new
animal varieties and have enacted laws to do so.
However, a patent protection system is not economically feasible for
China. Because the initial acquisition prices and subsequent royalty fees
can be very costly, China may not be able to afford the rights to many bio-
technological inventions. In particular, Chinese farmers may be deprived of
the benefits of genetically improved agricultural livestock. Instead, a nar-
rower sui generis protection system similar to the Plant Variety Regulations
would be more appropriate.
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